Intramuscular Use of Rabies Immunoglobulin may be Dangerously Interfering with Rabies Vaccine Immune Response
Abstract
India reports the highest number of dog bites and consequent rabies deaths in the world. Though rabies vaccines (RV) and rabies immunoglobulins (RIG) are covered under the Free Drugs Initiative of National Health Mission (NHM) of Government of India, still their shortages are a regular feature all over the country mainly due to exponential increase in dog bite cases over the years and the use of high dose-high-cost human rabies post-exposure prophylaxis (PEP). In this context, we need to implement the low dose-low-cost human rabies PEP as recommended by the World Health Organization (WHO) in its recent Rabies Prophylaxis Guidelines 2018.1 High potency of RVs and RIGs available in the Indian market further necessitates using low dose-low-cost PEP.
DOI: https://doi.org/10.24321/0973.5038.202601
How to cite this article:
Bharti O K. Intramuscular Use of Rabies Immunoglobulin may be Dangerously Interfering with Rabies Vaccine Immune Response. APCRI J. 2026; 28(1): 26-28.
References
WHO Expert Consultation on Rabies: WHO TRS N°1012;
https://www.who.int/publications/i/item/WHOTRS-1012
Bharti OK, Madhusudana SN, Gaunta PL, Belludi AY — Local infiltration of rabies immunoglobulins without systemic intramuscular administration: An alternative cost effective approach for passive immunization against rabies. Hum Vaccin Immunother 2016; 12(3): 837-42. doi:10.1080/ 21645515.2015.1085142;
https://pubmed.ncbi.nlm.nih.gov/26317441/
Bose A, Munshi R, Tripathy RM, Madhusudana SN, Harish BR, Thaker S, Mahendra BJ, Gunale B, Gogtay NJ, Thatte UM, Mani RS, Manjunath K, George K, Yajaman AB, Sahai A, Dhere RM, Alex RG, Adhikari DD, Abhilash, Raghava V, Kumbhar D, Behera TR, Kulkarni PS. A randomized non-inferiority clinical study to assess postexposure prophylaxis by a new purified vero cell rabies vaccine (Rabivax-S) administered by intramuscular and intradermal routes. Vaccine. 2016 Sep 14;34(40):4820- 6. doi: 10.1016/j.vaccine.2016.08.005. Epub 2016 Aug 21. PMID: 2755453; https://pubmed.ncbi.nlm.nih.gov/27554534/
Gogtay NJ, Munshi R, Ashwath Narayana DH, Mahendra BJ, Kshirsagar V, Gunale B, Moore S, Cheslock P, Thaker S, Deshpande S, Karande S, Kumbhar D, Ravish HS, Harish BR, Pisal SS, Dhere R, Parulekar V, Blackwelder WC, Molrine DC, Kulkarni PS. Comparison of a Novel Human Rabies Monoclonal Antibody to Human Rabies Immunoglobulin for Post exposure Prophylaxis: A Phase 2/3, Randomized, Single-Blind, Non inferiority, Controlled Study. Clin Infect Dis. 2018 Jan 18;66(3):387- 395. doi: 10.1093/cid/cix791. PMID: 29020321;
